RDN Lessons Learned: An Interview with Medtronic’s Jason Weidman

article image

While the initial hype surrounding RDN has largely disappeared, Medtronic’s efforts over the past seven years may finally be about to pay off—in a big way, the company hopes. We speak with the head of its renal denervation group about MDT’s ongoing clinical programs and upcoming US regulatory submission, and its path to a potentially enormous market.

More than a decade after Medtronic plc entered the renal denervation (RDN) market with the purchase of Ardian, and seven years after the high-profile failure of the first sham-controlled RDN trial, the company finally has US approval within its sights. It’s been a long and bumpy road, but Medtronic believes the payoff to come over the next five to 10 years will be well worth the effort.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: